Silver Book Fact

According to the Pharmaceutical Research and Manufacturers of America, a medicine in development targets CA125, a surface protein, or antigen, that is released in excess quantities by some ovarian cancers. The medicine, a monoclonal antibody, would stimulate the immune system to attack the protein–killing the tumors.

The Lewin Group. Saving Lives, Saving Money: Dividends for Americans investing in Alzheimer research. Falls Church, VA: The Lewin Group; 2004

Reference

Title
Saving Lives, Saving Money: Dividends for Americans investing in Alzheimer research
Publisher
The Lewin Group
Publication Date
2004
Authors
The Lewin Group

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • According to the Pharmaceutical Research and Manufacturers of America, a medicine currently in development may delay the worsening of liver cancer. The medicine is an oral signal transduction inhibitor…  
  • Following the current path, breast cancer incidence rate will increase by 50.8% between 2003 and 2023. If an alternative path is taken, cases will increase by 32.2% between 2003 and…  
  • Without screening and adjuvant therapy, the death rate for breast cancer would have increased by about 30 percent between 1975 and 2000.  
  • The overall five-year survival rate for men with prostate cancer is 99 percent—up from 43 percent in 1975.  
  • An experimental drug may help those women whose breast cancer worsens despite use of other therapies. The medicine was shown in studies to nearly double the time breast cancer…